AzurRX Biopharma Priced, Nasdaq: AZRX

Developing non-systemic biologics for gastrointestinal disorders.

Industry: Health Care

Latest Trade: $2.98 0.00 (0.0%)

First Day Return: -0.4%

Return from IPO: -45.8%

Industry: Health Care

We are engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. Non-systemic biologics are non-absorbable drugs that act locally without reaching the systemic circulation, i.e. the intestinal lumen, skin or mucosa.  Our current product pipeline consists of two therapeutic proteins under development. MS1819 - an autologous (from the same organism) yeast recombinant lipase for exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis. A recombinant lipase is an enzyme that breaks up fat molecules, which is created from new combinations of genetic material in yeast. AZX1101 - a recombinant ß-lactamase combination of bacterial origin for the prevention of hospital-acquired infections by resistant bacterial strains induced by parenteral administration of ß-lactam antibiotics, as well as prevention of antibiotic-associated diarrhea. A recombinant ß-lactamase is an enzyme that breaks up molecules with a beta-lactam ring as is often seen in antibiotics, which is created from new combinations of genetic material in yeast.
more less
IPO News for AzurRX Biopharma
more
IPO Data
IPO File Date 07/13/2016
Offer Price $5.50
Price Range $5.50 - $5.50
Offer Shares (mm) 1.0
Deal Size ($mm) $5
IPO Data
IPO Date 10/11/2016
Offer Price $5.50
Price Range $5.50 - $5.50
Offer Shares (mm) 1.0
Deal Size ($mm) $5
Underwriters
more
Company Data
Headquarters Brooklyn, NY
Founded 2007
Employees 12
Website www.azurrx.com